Articles related to CLINICAL TRIALS

Pembrolizumab Enhances Outcomes in Early-Stage NSCLC: A Phase 3 Trial Analysis In the pursuit of improved treatment outcomes for early-stage non-small-cell lung cancer (NSCLC), a phase 3 trial evaluated the efficacy of perioperative pembrolizumab. “Among patients with resectable, early-stage NSCLC, neoadjuvant pembrolizumab plus chemotherapy followed by resection and adjuvant pembrolizumab significantly improved event-free survival, major pathological response, and pathological complete response as compared with neoadjuvant chemotherapy alone followed by surgery.” Study Conclusions, KEYNOTE-671 ClinicalTrials.gov number, NCT03425643

A Randomized, Controlled, Double-Blind Trial Analyzing Colchicine’s Role in Reducing Knee and Hip Replacement Incidences An exploratory analysis of the LoDoCo2 randomized trial has led to a promising correlation between low-dose colchicine treatment and a reduced incidence of knee and hip replacements.

Cilta-cel CAR-T-cell therapy: A ray of hope for refractory multiple myeloma patients. A new study on ciltacabtagene autoleucel CAR-T-cell therapy (cilta-cel) shows promise for relapsed/refractory multiple myeloma (RRMM) patients. Published in Blood, the study led by Dr. Adam Cohen from the University of Pennsylvania, focuses on patients with previous exposure to noncellular anti-B-cell maturation antigen (BCMA) therapies. The team’s objective was achieving the primary endpoint of minimal residual disease (MRD) negativity, alongside multiple secondary endpoints. They tested on patients above 18 with RRMM, progressive disease within 12 months of their last treatment or six months of prior therapy, and measurable disease at baseline. They conducted a multicohort study, primarily focusing on cohort C which entailed cilta-cel treatment. A total of 20 patients met the eligibility criteria and received cilta-cel. Among them, 35% had BsAb as their latest anti-BCMA treatment, while 65% had ADC. With a median follow-up of 11.3 months, 7 patients achieved MRD negativity. The overall response rate stood at 60%, with 55% achieving very good partial response (VGPR) or better, and 30% achieving complete remission (CR) or better. However, all patients experienced treatment-emergent adverse events, majorly grade 3 to 4 cytopenias. Most of these cytopenia events recovered to […]

This article reviews the novel CXCR4 inhibitor motixafortide and its use in hematopoietic stem-cell mobilization. We present a history of stem-cell mobilization and update of recent innovations in novel mobilization strategies. Hematopoietic stem-cell mobilization is a crucial step in autologous stem-cell transplantation. Motixafortide is a novel CXCR4 inhibitor that has been shown in preclinical and clinical trials to mobilize hematopoietic stem cells (HSCs) for transplantation. The drug has extended in vivo activity (>48 h) and high affinity (Ki, 0.32 nM). In a phase 1, two-part study, motixafortide administered to healthy subjects was safe, well tolerated, and led to a rapid and robust increase in the number of circulating HSCs. Motixafortide has been evaluated in a randomized phase 3 trial for autologous transplantation in multiple myeloma. The study showed that the combination of motixafortide and granulocyte colony-stimulating factor (G-CSF) was superior to G-CSF alone in terms of the number of CD34+ cells collected and the time to engraftment. The drug has also been evaluated in combination with plerixafor, another CXCR4 inhibitor, in a phase 1/2 study for autologous transplantation in multiple myeloma. The study showed that the combination of motixafortide and plerixafor was safe and effective in mobilizing HSCs. Motixafortide has […]

ASCO 2023 abstracts: a glimpse into groundbreaking advancements in the oncology field. At the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Gilead Sciences and Kite Oncology are set to present 30 abstracts. Their data underscores their leadership in hard-to-treat cancers, notably metastatic breast cancer. In addition, they highlight a growing presence in lung cancer and other tumor types. Trodelvy® (sacituzumab govitecan-hziy) emerges as a promising treatment for HR+/HER2- metastatic breast cancer (mBC) with the final overall survival (OS) results from the Phase 3 TROPiCS-02 study. Its efficacy extends to metastatic urothelial cancer (UC) and advanced endometrial cancer, reinforcing its pan-tumor potential. Moreover, Yescarta® (axicabtagene ciloleucel) offers a ray of hope for adult patients with relapsed/refractory large B-cell lymphoma (LBCL). Notably, this CAR T-cell therapy demonstrates a statistical improvement over standard care in overall survival, marking a significant medical breakthrough. Gilead’s oncology pipeline, particularly for lung cancer, is expanding. The ongoing late-stage development program evaluates Trodelvy in non-small cell lung cancer (NSCLC). Also, the updated interim analysis of ARC-7, evaluating domvanalimab in first-line NSCLC, will be presented. Presentations at ASCO 2023 will also share trial updates from ongoing studies in lung cancer, triple-negative breast cancer, UC, and other solid […]

Diving into intensive systolic BP treatment unveils intriguing cognitive benefits according to a secondary analysis of the SPRINT trial. The SPRINT trial has shed fresh light on the impact of intensive systolic blood pressure (SBP) treatment on cognitive health. Out of 7,918 participants, a significant majority with higher baseline risk of dementia or mild cognitive impairment (MCI) revealed marked cognitive improvements with intensive SBP treatment. This marks a leap forward in understanding SBP treatment’s role in cognitive function preservation. In the comprehensive secondary analysis, patients were meticulously followed up over a median of four years. To streamline the study, two SBP treatment targets were identified: intensive, set at less than 120 mm Hg, and standard, at less than 140 mm Hg. The data collected showcased 765 and 828 primary outcome events in intensive and standard treatment groups, respectively. Consequently, it confirmed intensive SBP treatment’s potential in reducing the risk of MCI or dementia. Digging deeper into the data, certain trends emerged. Older age, Medicare enrollment, and higher baseline serum creatinine levels correlated with a higher risk of the primary outcome. Conversely, enhanced baseline cognitive functioning and active employment status signified lower risk. Interestingly, higher baseline risk connected directly with greater […]